The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Alosetron, a 5‐HT 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
Open accessAbstract
Background: Alosetron is a potent and selective 5‐HT 3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non‐constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double‐blind, placebo‐controlled with a two‐way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio‐opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X‐ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients ( P =0.128), which was confirmed in controls ( P =0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non‐constipated irritable bowel syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Drugs acting as antagonists at the 5-HT 3 receptor are also licensed for IBS-D. These include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral hypersensitivity and alter rectal compliance. [231][232][233]”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [231]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“5-HT3 antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity”
From Irritable bowel syndrome (2020) · cites this paper as [119]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“5-HT3 antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity”
From Irritable bowel syndrome (2020) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Simplified assessment of segmental colonic transit
Metcalf, A. M., Phillips, S. F., Zinsmeister, A. R., MacCarty, R. L., Beart, R. W., & Wolff, B. G. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90837-7 · Cited by 928
15 Design and Analysis of Cross-Over Trials
Kenward, M. G., & Jones, B. C. (2007) · Handbook of statistics · doi:10.1016/s0169-7161(07)27015-4 · Cited by 873
A new method for studying gut transit times using radioopaque markers
Hinton, J., Lennard‐Jones, J. E., & Young, A. C. (1969) · Gut · doi:10.1136/gut.10.10.842 · Cited by 838
Bowel Patterns Among Subjects Not Seeking g Health Care
Drossman, D. A., Sandler, R. S., McKee, D. C., & Lovitz, A. J. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80186-8 · Cited by 711
Design and Analysis of Cross-Over Trials
Jones, B. C., & Kenward, M. G. (1989) · Chapman & Hall/CRC eBooks · doi:10.4324/9780203009277 · Cited by 694
Production and Excretion of Hydrogen Gas in Man
Levitt, M. D. (1969) · New England Journal of Medicine · doi:10.1056/nejm196907172810303 · Cited by 586
Koch, G. G. (1972) · Biometrics · doi:10.2307/2556170 · Cited by 465
Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters
Heaton, K. W., O'Donnell, L. J. D., Braddon, F., Mountford, R. A., Hughes, A., & Cripps, P. J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90320-x · Cited by 382
Cann, P. A., Read, N. W., Brown, C., Hobson, N., & Holdsworth, C. D. (1983) · Gut · doi:10.1136/gut.24.5.405 · Cited by 365
Research works printed but not linked: 3
- MayerEA MunakataJ MertzH LemboT BernsteinCN.Visceral hyperalgesia and irritable bowel syndrome. In: Gebhert GF ed. Visceral Pain Progress in Pain Research and Management Vol 5. Seattle USA: IASP Press 1995: 429–68.
- Thompson WG, 1992, Functional bowel disease and functional abdominal pain. Working team report, Gastroenterol Int, 5, 75
- Lubke HJ, 1988, 5‐HT3 receptors have minimal effects on normal gut function, Gastroenterology, 94, A271
Cited by
Sorted by citations
Items 101–132 of 132
Nishiyama, H., Mizuta, Y., Isomoto, H., Takeshima, F., Omagari, K., Miyahara, Y., Murata, I., & Kohno, S. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000030086.03506.c7 · Cited by 8
The role of serotonin and its pathways in gastrointestinal disorders
Bellini, M., Fornai, M., Usai–Satta, P., Bronzini, F., Bassotti, G., Blandizzi, C., & Colucci, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00009-7 · Cited by 7
Zeng, X., He, J., Li, X., Chen, P., Zuo, J., Cai, X., Fan, Z., & Qu, J. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04019-3 · Cited by 7
Persistent Travelers' Diarrhea
Connor, B. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-03453-1.10055-0 · Cited by 6
Mast Cells and Intestinal Motility Disorders (Mastocytic Enteritis/Colitis)
Schaeffer, D. F., Kirsch, R., & Riddell, R. H. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2123-6 · Cited by 5
Novel therapies in the treatment of irritable bowel syndrome
Berrada, D., & Lembo, T. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.635 · Cited by 5
Haagsma, J. A. (2010) · RePub (Erasmus University Rotterdam) · Cited by 5
Tyers, M. B. (2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00569-6 · Cited by 5
Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction
Camilleri, M., Sarnelli, G., Andresen, V., Meerveld, B. G., Howden, C. W., Izzo, A. A., & Jones, K. L. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.02.010 · Cited by 3
Hamano, H., Mitsuhashi, C., Suzuki, Y., Zamami, Y., Tsujinaka, K., Okada, N., Niimura, T., Hayama, T., Imai, T., Ishida, S., et al. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00609 · Cited by 3
Drugs Affecting Visceral Sensitivity: Ready for the Prime Time?
Delvaux, M. M., & Gay, G. (2006) · Digestive Diseases · doi:10.1159/000090313 · Cited by 3
Andrews, M. B., & Adler, D. G. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2490841 · Cited by 2
Pathophysiology of Irritable bowel syndrome:The role of brain-gut axis and serotoninergic receptors
Karamanolis, D. G., & Kyrlagkitsis, I. (2007) · Annals of Gastroenterology · Cited by 2
Approche du malade avec une diarrhée fonctionnelle
Delvaux, M., & Gay, G. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73196-7 · Cited by 1
Gaus, O. V., & Livzan, M. A. (2023) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2023-33-2-34-44 · Cited by 2
Videlock, E. J., & Chang, L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch75 · Cited by 2
Epidemiology, pathogenesis and treatment of irritable bowel syndrome
Nam, J. H., Alnoah, Z., Yenumula, S. R., & Murthy, S. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.8.1213 · Cited by 1
Lupianez‐Merly, C., Dilmaghani, S., Jencks, K. J., Eckert, D. J., Ryks, M. D., Burton, D. B., & Camilleri, M. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14917 · Cited by 1
Halliez, M. C. M. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27133 · Cited by 1
Persistent Travelers' Diarrhea
Connor, B. A., & Shlim, D. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-1076-8.00021-1 · Cited by 1
Enteric serotonin interneurons: connections and role in intestinal movement
Neal, K. (2008) · Minerva Access (University of Melbourne)
Colonic sensory and motor function in irritable bowel syndrome and diverticular disease
Clemens, C. H. M. (2003) · Utrecht University Repository (Utrecht University)
Posibilidades farmacológicas de modulación de la percepción visceral
Juan, A. P., & Mearin, F. (2004) · Gastroenterología y Hepatología · doi:10.1016/s0210-5705(03)70508-1
Irritable Bowel Syndrome (IBS) – Diagnosis dan Penatalaksanaan
Jacobus, D. J. (2014) · Cermin Dunia Kedokteran
Functional Bowel Disorders for the Colorectal Surgeon
Ayscue, J. M., & Kumar, A. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-25970-3_62
Persistent Gastrointestinal Symptoms in the Ill-Returning Traveler
Riddle, M. S., Shlim, D. R., & Connor, B. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54696-6.00021-5
Wojczynski, M. K. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/jay1-j823
Flupirtine enhances NHE-3-mediated Na+ absorption in rat colon via an ENS-dependent mechanism
Nickerson, A. J., & Rajendran, V. M. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2021
Intelligent information retrieval and web mining architecture using soa
Chang, P. H., & El-Bathy, N. (2010) · ProQuest LLC eBooks
Silva, H. J. D. (2002) · Side effects of drugs annual · doi:10.1016/s0378-6080(02)80043-5
Mechanostimulation of neuroendocrine cells and their clinical relevance
Brayer, M., Zderic, V., & Jeremic, A. M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05438-1
Yu, L. C.-H., Huang, C.-Y., Lin, C.-Y., Tsai, Y.-S., Chang, Y.-C., Huang, C.-W., Chao, Z.-L., & Kuo, W.-T. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1903390
Metadata
- Authors
- Houghton, Foster, & Whorwell
- Affiliations
- Manchester University NHS Foundation Trust (GB)
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-06
- Volume
- 14
- Issue
- 6
- Pages
- 775-782
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2049197933
- Cited by
- 132
- References
- 34
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 2 · 2019: 5 · 2018: 3 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 2 · 2012: 3
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Keywords
- alosetron, 5-HT3 receptor antagonists, irritable bowel syndrome, colonic transit, whole gut transit, small intestinal transit, radio-opaque markers, breath hydrogen, abdominal radiography
- MeSH terms
- Adult, Carbolines, Colon, Colonic Diseases, Functional, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Intestine, Small, Male, Middle Aged, Serotonin Antagonists, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
